Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 29 peer-reviewed journal articles Updated

Treatment Strategies and Medical Management

At a Glance

CFH deficiency treatment is individualized: C5 inhibitors are established for many patients with aHUS, while C3G often needs kidney care or other complement treatments. Meningococcal vaccines, preventive antibiotics, and specialist monitoring are important if treatment is reduced or stopped.

Treating Complement Factor H (CFH)-related disease is a balancing act. Your medical team must work to “quiet” an overactive immune system while simultaneously protecting you from the infections that your immune system is normally supposed to fight [1][2].

Because CFH deficiency can lead to either aHUS or C3G, your treatment plan will be highly individualized depending on your phenotype and country-specific approvals [3].

Established Therapy for aHUS: C5 Inhibitors

For many appropriate patients with complement-mediated aHUS, the established therapy is a class of drugs called C5 inhibitors. These medications, including eculizumab and ravulizumab, act like a physical shield that blocks the final, most destructive stage of the complement system [4][5].

  • Individualized Dosing: These drugs are administered via intravenous infusion. The dosing schedules (e.g., weekly loading doses followed by biweekly or 4–8 week maintenance intervals) are highly individualized based on your age, body weight, and indication [6][7][8].
  • C3G Management: Note that C5 inhibitors are not automatically first-line for C3G. C3G management may focus on blood pressure and proteinuria control, renin-angiotensin-system blockade, selected immunosuppression, clinical trials, and newer proximal alternative-pathway therapies depending on your jurisdiction [9].

The Essential Safety Protocol

While C5 inhibitors are effective, they lower your ability to fight off meningococcal disease, a severe infection of the brain and blood [10]. To manage this risk, doctors follow a strict safety protocol that you must be an active partner in.

1. Vaccination

You must receive meningococcal vaccines for groups ACWY and B [11][12]. The schedule and boosters depend on your age, country, and the product used. If your treatment is an emergency and cannot wait two weeks, vaccination should be given as soon as possible alongside immediate antibacterial protection [13].

2. Prophylactic Antibiotics

Most specialists will prescribe a preventative antibiotic. This is not a universal identical regimen; it is individualized based on age, allergy, local resistance guidelines, and duration of therapy [14][10]. This provides a second layer of defense against bacteria [15].

3. The Patient Safety Card

You will be given a patient safety card that explains your risk to other doctors. You must carry this at all times. Any fever or acute illness while receiving a C5 inhibitor requires immediate medical advice because vaccination and antibiotics do not eliminate the risk, and other serious Neisseria infections can occur [16][10].

Treating the “Acquired” (Antibody) Subtype

If your deficiency is caused by anti-CFH autoantibodies, your treatment may involve more than just blocking the complement system [17]. Your doctors may also focus on removing the antibodies themselves:

  • Plasma Exchange (Plasmapheresis): This process filters your blood to physically remove the harmful antibodies, often used early in severe cases [17][18].
  • Immunosuppression: To stop your body from making new antibodies, you may be prescribed drugs like rituximab, cyclophosphamide, or steroids [19][20].

Using these in combination in selected severe cases can improve outcomes, though these drugs carry bleeding, infection, and fertility risks that must be weighed carefully [21][22].

The Decision to Stop Treatment

In the past, patients were told they must stay on complement inhibitors for life. Today, the conversation is changing, but there is no universal six-to-twelve-month rule [23].

Discontinuation is a specialist-led, shared decision with a written laboratory monitoring and rapid-retreatment plan. You must not stop or restart a complement inhibitor without your treating team [24][25].

  • Variable Relapse Risk: Relapse risk varies heavily with genotype, prior TMA, kidney status, and phenotype. Patients with mutations in the CFH gene are generally at a much higher risk of relapsing if they stop treatment [26][27].
  • Monitoring Limits: Urine checks alone cannot safely monitor withdrawal. You must follow the exact post-withdrawal blood testing schedule defined by your specialist [26][28]. For many high-risk patients, staying on maintenance therapy is the safest way to protect their long-term health [19][29].

Common questions in this guide

Which treatments are used for CFH deficiency?
Treatment depends on whether CFH deficiency is causing complement-mediated atypical hemolytic uremic syndrome (aHUS) or C3 glomerulopathy (C3G). C5 inhibitors such as eculizumab and ravulizumab are established options for many patients with aHUS, while C3G may be managed with blood pressure and proteinuria control, immune treatment, clinical trials, or newer complement medicines depending on local approvals.
Why are meningococcal vaccines important with C5 inhibitors?
C5 inhibitors weaken part of the immune response that helps protect against meningococcal disease, a potentially life-threatening infection. People receiving them generally need vaccines covering meningococcal groups ACWY and B, with booster timing based on age, country, and vaccine product.
Should I take antibiotics while receiving a C5 inhibitor?
Many specialists prescribe a preventive antibiotic during C5-inhibitor treatment, but the drug and schedule depend on age, allergies, local resistance guidance, and treatment duration. Preventive antibiotics lower risk but do not remove it, so fever or other acute illness needs immediate medical advice.
How are anti-CFH antibodies treated?
When CFH deficiency is caused by anti-CFH autoantibodies, doctors may use plasma exchange to remove antibodies from the blood and immunosuppressive medicines to reduce new antibody production. Options may include rituximab, cyclophosphamide, or steroids, and the risks of infection, bleeding, and fertility effects must be weighed.
Can I stop my C5 inhibitor if I feel well?
Stopping a C5 inhibitor may be considered for some patients, but there is no universal schedule and the decision must be made with a complement specialist. A written blood-test monitoring and rapid-retreatment plan is needed because relapse risk varies and can be higher in people with CFH gene mutations.
What should I do if I develop a fever or stiff neck during treatment?
Seek urgent medical advice or emergency care because C5 inhibitors can increase the risk of meningococcal and other serious Neisseria infections. Vaccination and preventive antibiotics reduce risk but do not eliminate it, so carry your patient safety card and tell clinicians that you receive a C5 inhibitor.

Get notified when new evidence is published on complement factor H deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (29)
  1. 1

    Atypical hemolytic uremic syndrome: Consensus of diagnosis and treatment in Taiwan.

    Tseng MH, Lin SH, Tsai JD, et al.

    Journal of the Formosan Medical Association = Taiwan yi zhi 2023; (122(5)):366-375 doi:10.1016/j.jfma.2022.10.006.

    PMID: 36323601
  2. 2

    Targeting complement in atypical hemolytic and uremic syndrome: development and current status of eculizumab and ravulizumab

    Maillard N, Provot F

    Nephrologie & therapeutique 2026; (21(7)):587-595 doi:10.1684/ndt.2025.160.

    PMID: 41487041
  3. 3

    Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.

    Greenbaum LA, Fila M, Ardissino G, et al.

    Kidney international 2016; (89(3)):701-11.

    PMID: 26880462
  4. 4

    Ravulizumab: First Global Approval.

    McKeage K

    Drugs 2019; (79(3)):347-352 doi:10.1007/s40265-019-01068-2.

    PMID: 30767127
  5. 5

    A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab.

    Schalk G, Kirschfink M, Wehling C, et al.

    Pediatric nephrology (Berlin, Germany) 2015; (30(6)):1039-42 doi:10.1007/s00467-015-3078-6.

    PMID: 25752761
  6. 6

    Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern.

    García Monteavaro C, Peralta Roselló C, Quiroga B, et al.

    Case reports in nephrology 2016; (2016()):7471082 doi:10.1155/2016/7471082.

    PMID: 28025630
  7. 7

    The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.

    Ariceta G, Dixon BP, Kim SH, et al.

    Kidney international 2021; (100(1)):225-237 doi:10.1016/j.kint.2020.10.046.

    PMID: 33307104
  8. 8

    The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.

    Tanaka K, Adams B, Aris AM, et al.

    Pediatric nephrology (Berlin, Germany) 2021; (36(4)):889-898 doi:10.1007/s00467-020-04774-2.

    PMID: 33048203
  9. 9

    C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.

    Garg N, Zhang Y, Nicholson-Weller A, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2018; (33(12)):2260-2265 doi:10.1093/ndt/gfx369.

    PMID: 29370420
  10. 10

    High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine.

    McNamara LA, Topaz N, Wang X, et al.

    MMWR. Morbidity and mortality weekly report 2017; (66(27)):734-737 doi:10.15585/mmwr.mm6627e1.

    PMID: 28704351
  11. 11

    Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.

    Mbaeyi SA, Bozio CH, Duffy J, et al.

    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports 2020; (69(9)):1-41 doi:10.15585/mmwr.rr6909a1.

    PMID: 33417592
  12. 12

    Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.

    Jodele S, Dandoy CE, Danziger-Isakov L, et al.

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2016; (22(7)):1337-1340 doi:10.1016/j.bbmt.2016.03.032.

    PMID: 27060440
  13. 13

    Meningococcal prophylaxis in neurological diseases treated with complement inhibitors: an expert consensus for Germany, Austria, and Switzerland.

    Berthele A, Aktas O, Ayzenberg I, et al.

    Therapeutic advances in neurological disorders 2026; (19()):17562864261442558 doi:10.1177/17562864261442558.

    PMID: 42137634
  14. 14

    Current practices in antibiotic prophylaxis for patients on complement inhibitors: a multicenter survey across ERN ERKnet centers.

    Sciascia S, Terzolo E, Fenoglio R, et al.

    Clinical kidney journal 2026; (19(9)):sfag282 doi:10.1093/ckj/sfag282.

    PMID: 42707644
  15. 15

    Antimeningococcal Protection in Patients Receiving Terminal Complement Inhibitors.

    Vujović A, Schaefer F, Sellier-Leclerc AL, et al.

    Kidney international reports 2026; (11(2)):103700 doi:10.1016/j.ekir.2025.11.025.

    PMID: 41550525
  16. 16

    Infection risk mitigation with complement inhibitors in kidney disease.

    Berghmans M, Seghers F, Mirioglu S, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2026; doi:10.1093/ndt/gfag113.

    PMID: 42175904
  17. 17

    Deficiency of CFHR plasma proteins and autoantibody positive hemolytic uremic syndrome: treatment rationale, outcomes, and monitoring.

    Iorember F, Nayak A

    Pediatric nephrology (Berlin, Germany) 2021; (36(6)):1365-1375 doi:10.1007/s00467-020-04652-x.

    PMID: 32529325
  18. 18

    A systematic review of short-term outcomes in patients with anti-factor H associated atypical HUS managed with plasma exchanges versus eculizumab.

    Sinha A, Bindal T, Zotta F, et al.

    Pediatric nephrology (Berlin, Germany) 2026; (41(12)):4369-4378 doi:10.1007/s00467-026-07309-3.

    PMID: 42101481
  19. 19

    Clinical and Immunological Profile of Anti-factor H Antibody Associated Atypical Hemolytic Uremic Syndrome: A Nationwide Database.

    Puraswani M, Khandelwal P, Saini H, et al.

    Frontiers in immunology 2019; (10()):1282 doi:10.3389/fimmu.2019.01282.

    PMID: 31231391
  20. 20

    Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP.

    Kelen K, Horváth O, Kis É, et al.

    International journal of molecular sciences 2023; (24(18)) doi:10.3390/ijms241814389.

    PMID: 37762692
  21. 21

    Deficiency of complement factor H-related proteins and autoantibody-positive hemolytic uremic syndrome in an infant with combined partial deficiencies and autoantibodies to complement factor H and ADAMTS13.

    Michael M, Turner N, Elenberg E, et al.

    Clinical kidney journal 2018; (11(6)):791-796 doi:10.1093/ckj/sfy010.

    PMID: 30524124
  22. 22

    Clinical features of children with anti-CFH autoantibody-associated hemolytic uremic syndrome: a report of 8 cases.

    Li Q, Kong X, Tian M, et al.

    Renal failure 2022; (44(1)):1061-1069 doi:10.1080/0886022X.2022.2089167.

    PMID: 35730179
  23. 23

    Defining treatment duration in atypical hemolytic uremic syndrome in adults: a clinical and pathological approach.

    Laurence J

    Clinical advances in hematology & oncology : H&O 2020; (18(4)):221-230.

    PMID: 32628650
  24. 24

    Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study.

    Bouwmeester RN, Duineveld C, Wijnsma KL, et al.

    Kidney international reports 2023; (8(1)):91-102 doi:10.1016/j.ekir.2022.10.013.

    PMID: 36644349
  25. 25

    Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials.

    Dixon BP, Kavanagh D, Aris ADM, et al.

    Kidney medicine 2024; (6(8)):100855 doi:10.1016/j.xkme.2024.100855.

    PMID: 39105067
  26. 26

    Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.

    Fakhouri F, Fila M, Provôt F, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2017; (12(1)):50-59 doi:10.2215/CJN.06440616.

    PMID: 27799617
  27. 27

    Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation.

    Acosta-Medina AA, Moyer AM, Go RS, et al.

    Blood advances 2023; (7(3)):340-350 doi:10.1182/bloodadvances.2021006416.

    PMID: 35533258
  28. 28

    Long-term outcome and management of complement-mediated thrombotic microangiopathy/aHUS.

    Afshar-Kharghan V

    Hematology. American Society of Hematology. Education Program 2025; (2025(1)):147-153 doi:10.1182/hematology.2025000700C.

    PMID: 41347985
  29. 29

    Anti-CFH-associated hemolytic uremic syndrome: do we still need plasma exchange?

    Ferri M, Zotta F, Donadelli R, et al.

    Pediatric nephrology (Berlin, Germany) 2024; (39(11)):3263-3269 doi:10.1007/s00467-024-06373-x.

    PMID: 38632123

This page explains treatment and safety planning for CFH deficiency for educational purposes only and does not replace advice from your treating specialist. Do not start, change, or stop complement therapy or antibiotics without medical guidance.

Guide contents complement factor H deficiency
Research & Literature
04 The Diagnostic Journey and Essential Lab Tests 06 Long-Term Monitoring and Survivorship